RETRACTED: The preoperative platelet–lymphocyte ratio versus neutrophil–lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma?

Abstract

The preoperative PLR is superior to NLR as an independent indicator in predicting disease-free survival and overall survival in patients who undergo oral cancer resection for OSCC.

Platelet count and platelet‐lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta‐analysis

“…Therefore, meta-analyses were conducted with a random effect model, using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ). However, only 4 studies 38,42,44,46 were subjected to subgroup analyses for disease sites because the other studies reported the HRs of patients with different affected sites together. Most of the included studies dichotomized patients into 2 groups according to the platelet count or PLR.…”

“…The HRs for DSS were reported in 3 studies and ranged from 0.95 to 1.62; none were statistically significant 37,39,51 ( Figure 2B). Table 2 37,38,[41][42][43][44][45][46]51 shows the characteristics of the included studies for PLR analysis. The pooled HR for DSS was 1.13 (95% CI 0.90-1.43), and the result was not statistically significant.…”

“…The pooled analysis for the 3 studies involved 1956 patients and is shown in Figure 2B. 38,[41][42][43][44][45][46]51 The outcomes analyzed in these studies were OS in 7 studies 37,38,[41][42][43][44]46 and DSS in 3 studies. The result was similar when any individual study was removed from the analysis (Supporting Information Figure S1B).…”

“…Table 2 37,38,[41][42][43][44][45][46]51 shows the characteristics of the included studies for PLR analysis. 38,[42][43][44]46 Cutoff values for dichotomization ranged from 112 to 150. All of the included studies were published after 2015 and were single-institution studies.…”

“…On the other hand, the information from blood samples demonstrates only the indirect consequences of cancer progression. [34][35][36][37][38][39][40][41][42][43][44][45][46] Among these studies, only 1 study was prospective. Moreover, blood markers are not affected by any heterogeneity within the tumor.…”